Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa (Q71958736)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

title

Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference

1 reference

N-Terminal Propeptide of Type III Collagen

1 reference

1 reference

1 reference

T Suou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

K Hosho

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Y Kishimoto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Y Horie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

H Kawasaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

language of work or name

English

0 references

publication date

1 August 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

page(s)

426-431

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

22 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Selective inhibition of human diploid fibroblast collagen synthesis by interferons

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Radioimmunoassay for type III procollagen peptide and its application to human liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Prediction of response to interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840220209

7 January 2021

Identifiers

DOI

10.1002/HEP.1840220209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7635409%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference